Abstract
Plasma concentrations of primidone and its metabolite phenobarbitone were monitored in 9 pregnant epileptic patients treated with primidone (and in 3 cases other antiepileptic drugs) given at constant doses throughout pregnancy and the Puerperium. Phenobarbitone plasma concentrations were monitored in another 6 patients given phenobarbitone itself. A trend towards increasing primidone plasma concentrations during the second quarter of pregnancy was evident in all patients, with a concomitant significant decrease in primidone-derived phenobarbitone plasma concentrations. A trend towards a lowering of plasma concentrations of phenobarbitone administered as such was confirmed. These results suggest the usefulness of a careful monitoring of primidone and primidone-derived phenobarbitone during pregnancy and the Puerperium. Discrepancies of findings with primidone and phenobarbitone are discussed in view of the possible mechanism involved.
| Original language | English |
|---|---|
| Pages (from-to) | 252-260 |
| Number of pages | 9 |
| Journal | Clinical Pharmacokinetics |
| Volume | 9 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1984 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Changes in Primidone/Phenobarbitone Ratio During Pregnancy and the Puerperium. / Battino, D.; Binelli, S.; Bossi, L.; Como, M. L.; Croci, D.; Cusi, C.; Avanzini, G.
In: Clinical Pharmacokinetics, Vol. 9, No. 3, 1984, p. 252-260.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Changes in Primidone/Phenobarbitone Ratio During Pregnancy and the Puerperium
AU - Battino, D.
AU - Binelli, S.
AU - Bossi, L.
AU - Como, M. L.
AU - Croci, D.
AU - Cusi, C.
AU - Avanzini, G.
PY - 1984
Y1 - 1984
N2 - Plasma concentrations of primidone and its metabolite phenobarbitone were monitored in 9 pregnant epileptic patients treated with primidone (and in 3 cases other antiepileptic drugs) given at constant doses throughout pregnancy and the Puerperium. Phenobarbitone plasma concentrations were monitored in another 6 patients given phenobarbitone itself. A trend towards increasing primidone plasma concentrations during the second quarter of pregnancy was evident in all patients, with a concomitant significant decrease in primidone-derived phenobarbitone plasma concentrations. A trend towards a lowering of plasma concentrations of phenobarbitone administered as such was confirmed. These results suggest the usefulness of a careful monitoring of primidone and primidone-derived phenobarbitone during pregnancy and the Puerperium. Discrepancies of findings with primidone and phenobarbitone are discussed in view of the possible mechanism involved.
AB - Plasma concentrations of primidone and its metabolite phenobarbitone were monitored in 9 pregnant epileptic patients treated with primidone (and in 3 cases other antiepileptic drugs) given at constant doses throughout pregnancy and the Puerperium. Phenobarbitone plasma concentrations were monitored in another 6 patients given phenobarbitone itself. A trend towards increasing primidone plasma concentrations during the second quarter of pregnancy was evident in all patients, with a concomitant significant decrease in primidone-derived phenobarbitone plasma concentrations. A trend towards a lowering of plasma concentrations of phenobarbitone administered as such was confirmed. These results suggest the usefulness of a careful monitoring of primidone and primidone-derived phenobarbitone during pregnancy and the Puerperium. Discrepancies of findings with primidone and phenobarbitone are discussed in view of the possible mechanism involved.
UR - http://www.scopus.com/inward/record.url?scp=0021368474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021368474&partnerID=8YFLogxK
U2 - 10.2165/00003088-198409030-00006
DO - 10.2165/00003088-198409030-00006
M3 - Article
C2 - 6734014
AN - SCOPUS:0021368474
VL - 9
SP - 252
EP - 260
JO - Clinical Pharmacokinetics
JF - Clinical Pharmacokinetics
SN - 0312-5963
IS - 3
ER -